Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Central Nervous System Disease

imatinib mesylate has been researched along with Central Nervous System Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dağlı, M; Keles Oğlu, KS; Koplay, M; Paksoy, Y; Sivri, M1
Annus, JK; Borbényi, Z; Marton, I; Nemes, A; Pósfai, É; Vecsei, L; Vörös, E1
Hamano, Y; Isobe, Y; Masuda, A; Oshimi, K; Sugimoto, K1
Baumann, M; Cerny, T; Koeberle, D; Sommacal, A1
Egorin, M; Ilaria, RL; Richardson, JA; Wolff, NC1

Reviews

1 review(s) available for imatinib mesylate and Central Nervous System Disease

ArticleYear
Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate.
    Internal medicine journal, 2009, Volume: 39, Issue:6

    Topics: Benzamides; Central Nervous System; Central Nervous System Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meningitis, Bacterial; Middle Aged; Piperazines; Pyrimidines

2009

Other Studies

4 other study(ies) available for imatinib mesylate and Central Nervous System Disease

ArticleYear
An atypical isolated CNS blast crisis in chronic myeloid leukaemia.
    British journal of hospital medicine (London, England : 2005), 2018, Aug-02, Volume: 79, Issue:8

    Topics: Aged; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System Diseases; Cytarabine; Glucocorticoids; Humans; Image Enhancement; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Methotrexate; Neuroimaging; Spinal Cord; Treatment Outcome

2018
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
    Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2015
Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
    Hematological oncology, 2012, Volume: 30, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Benzenesulfonates; Central Nervous System Diseases; Cladribine; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib

2012
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
    Blood, 2003, Jun-15, Volume: 101, Issue:12

    Topics: Animals; Benzamides; Blood-Brain Barrier; Bone Marrow; Brain Neoplasms; Central Nervous System Diseases; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperazines; Pyrimidines; Spinal Cord Neoplasms; Transfection

2003